- Home
- NHI vs PTGX Comparison
NHI vs PTGX Comparison
Compare NHI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHI
- PTGX
- Stock Information
- Founded
- NHI 1991
- PTGX 2006
- Country
- NHI United States
- PTGX United States
- Employees
- NHI N/A
- PTGX N/A
- Industry
- NHI Real Estate Investment Trusts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- NHI Real Estate
- PTGX Health Care
- Exchange
- NHI Nasdaq
- PTGX Nasdaq
- Market Cap
- NHI 3.5B
- PTGX 2.9B
- IPO Year
- NHI 1991
- PTGX 2016
- Fundamental
- Price
- NHI $72.47
- PTGX $47.47
- Analyst Decision
- NHI Buy
- PTGX Strong Buy
- Analyst Count
- NHI 5
- PTGX 8
- Target Price
- NHI $82.20
- PTGX $66.50
- AVG Volume (30 Days)
- NHI 264.5K
- PTGX 789.1K
- Earning Date
- NHI 05-05-2025
- PTGX 05-06-2025
- Dividend Yield
- NHI 4.96%
- PTGX N/A
- EPS Growth
- NHI 3.74
- PTGX N/A
- EPS
- NHI 3.16
- PTGX 0.86
- Revenue
- NHI $343,615,000.00
- PTGX $207,801,000.00
- Revenue This Year
- NHI $6.77
- PTGX N/A
- Revenue Next Year
- NHI $11.76
- PTGX $50.30
- P/E Ratio
- NHI $22.97
- PTGX $55.04
- Revenue Growth
- NHI 7.49
- PTGX N/A
- 52 Week Low
- NHI $64.00
- PTGX $27.00
- 52 Week High
- NHI $86.13
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- NHI 42.08
- PTGX 58.60
- Support Level
- NHI $71.75
- PTGX $45.43
- Resistance Level
- NHI $73.26
- PTGX $46.80
- Average True Range (ATR)
- NHI 1.39
- PTGX 1.54
- MACD
- NHI -0.30
- PTGX 0.34
- Stochastic Oscillator
- NHI 16.60
- PTGX 94.26
About NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.